RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 100 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,791 | +16.7% | 209 | -16.1% | 0.00% | – |
| Q2 2023 | $4,105 | +10.1% | 249 | +19.1% | 0.00% | – |
| Q1 2023 | $3,729 | -37.8% | 209 | 0.0% | 0.00% | – |
| Q4 2022 | $6,000 | +20.0% | 209 | 0.0% | 0.00% | – |
| Q3 2022 | $5,000 | +400.0% | 209 | -0.5% | 0.00% | – |
| Q2 2022 | $1,000 | -50.0% | 210 | 0.0% | 0.00% | – |
| Q1 2022 | $2,000 | 0.0% | 210 | 0.0% | 0.00% | – |
| Q4 2021 | $2,000 | -81.8% | 210 | -74.1% | 0.00% | – |
| Q3 2021 | $11,000 | -38.9% | 810 | -11.5% | 0.00% | – |
| Q2 2021 | $18,000 | -14.3% | 915 | -8.0% | 0.00% | – |
| Q1 2021 | $21,000 | -25.0% | 995 | +4.7% | 0.00% | – |
| Q4 2020 | $28,000 | +47.4% | 950 | +8.6% | 0.00% | – |
| Q3 2020 | $19,000 | +375.0% | 875 | +337.5% | 0.00% | – |
| Q2 2020 | $4,000 | +33.3% | 200 | 0.0% | 0.00% | – |
| Q1 2020 | $3,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 810,000 | $19,845,000 | 8.20% |
| NEA Management Company, LLC | 4,912,306 | $108,316,000 | 5.41% |
| Frazier Life Sciences Management, L.P. | 1,894,000 | $46,403,000 | 3.57% |
| RA Capital Management | 5,471,067 | $134,041,000 | 2.86% |
| Samsara BioCapital, LLC | 345,293 | $8,460,000 | 1.97% |
| Altium Capital Management LP | 170,000 | $4,165,000 | 1.53% |
| Parkman Healthcare Partners LLC | 187,989 | $4,606,000 | 1.31% |
| Rock Springs Capital Management LP | 1,760,865 | $43,141,000 | 1.11% |
| EAM Investors, LLC | 198,699 | $4,868,000 | 1.06% |
| Prosight Management, LP | 80,000 | $1,960,000 | 1.05% |